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Objectives: To use health economic modeling techniques to quantify and compare 
the clinical and economic outcomes associated with the use of subcutaneous inter-
feron beta-1a (scIFNβ 1a) vs. intramuscular interferon beta-1a (imIFNβ 1a) over 2 years 
in the management of relapsing forms of multiple sclerosis (MS) from a US health 
care payer perspective. MethOds: The 2-year decision analytic model was popu-
lated with IMS LifeLink Plus prevalence and treatment data, and clinical data from 
the EVIDENCE (EVidence of Interferon Dose-response: European North American 
Comparative Efficacy) study, a direct head-to-head comparison of 44 mcg scIFNβ 1a 
three times a week vs. 30 mcg imIFNβ 1a once a week. Relapse data from 16-month 
results were extrapolated for the 2-year model. Disease-modifying drug (DMD) costs 
were based on 2014 wholesale average cost with consideration of patient copay-
ment in the base case. The model was created with the ability to customize the rate 
of copayment as well as to incorporate contractual discounts, if desired. One-way 
sensitivity analyses were conducted on key parameters using alternate plausible 
values, including the rates of real-world DMD adherence. Results: For a hypotheti-
cal health plan with 1 million members, it is estimated that 911 patients with MS 
would be treated with DMDs. More relapses were avoided with scIFNβ 1a over 2 years 
(979) than with imIFNβ 1a over 2 years (778). The average cost-effectiveness of 44 mcg 
scIFNβ 1a was lower (more favourable) than the average cost-effectiveness of 30 mcg 
imIFNβ 1a ($123,854 vs. $148,749 per relapse avoided). Sensitivity analyses around 
model input values showed the model was robust and cost-effectiveness results 
were consistent. The model results are most sensitive to drug cost. cOnclusiOns: 
Cost-effectiveness assessment may facilitate the decision-making process in select-
ing MS treatments. Using the highest-quality clinical data (Level 1, head-to-head 
study, EVIDENCE), the cost-effectiveness of 44 mcg scIFNβ 1a was shown to be favour-
able compared with 30 mcg imIFNβ 1a.
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Objectives: To evaluate the cost-effectiveness of 44 mcg subcutaneous interferon 
beta-1a (scIFNβ 1a) and intramuscular interferon beta-1a (imIFNβ 1a) during the com-
parative and open-label extension phases of the EVIDENCE (EVidence of Interferon 
Dose-response: European North American Comparative Efficacy) study. MethOds: 
A decision analytic model from a US health care payer perspective was populated 
with 2-year data from the EVIDENCE study of imIFNβ 1a and 44 mcg scIFNβ 1a (com-
parative and open-label extension phases). EVIDENCE results showed that the annu-
alized relapse rate of 44 mcg scIFNβ 1a patients was 0.46 during the comparative 
phase and 0.34 during the open-label extension phase. The annualized relapse rate 
of imIFNβ 1a patients during the comparative phase was 0.64. imIFNβ 1a patients who 
switched to 44 mcg scIFNβ 1a for the open-label extension phase had an annualized 
relapse rate of 0.32. These data were used to model the cost-effectiveness of 44 mcg 
scIFNβ 1a and imIFNβ 1a patients during the comparative phase as well as for the 
combined comparative and open-label extension phases (for patients remaining 
on scIFNβ 1a throughout and for those switching from imIFNβ 1a in the comparative 
phase to scIFNβ 1a in the open-label extension). Disease-modifying drug (DMD) cost 
was based on 2014 wholesale average cost with consideration of patient copayment 
in the base case. Results: The cost-effectiveness for 44 mcg scIFNβ 1a and imIFNβ 1a 
during the comparative phase was $123,854 and $148,749 per relapse avoided, 
respectively. The cost-effectiveness of patients who remained on 44 mcg scIFNβ 1a 
throughout the study was $99,398 per relapse avoided, while the cost-effectiveness 
of imIFNβ 1a patients who switched to 44 mcg scIFNβ 1a for the open-label extension 
was $116,404 per relapse avoided. Sensitivity analyses showed that the model was 
robust and was most sensitive to DMD cost. cOnclusiOns: This decision analytic 
model evaluation shows that remaining on 44 mcg scIFNβ 1a and switching from 
imIFNβ 1a to 44 mcg scIFNβ 1a were cost-effective treatment strategies.
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Objectives: To assess the cost-effectiveness of Lacosamide (LCM) in the manage-
ment of epileptic partial onset seizures (POS) versus standard AED therapy in Greece, 
as well as its impact on the health care budget. MethOds: A cost-effectiveness 
model was developed simulating the treatment pathway of a hypothetical cohort of 
1000 patients over two years. A comprehensive literature search was conducted to 
identify local resource use data for medical, pharmaceutical and hospital treatment. 
Due to lack of relevant data, an expert panel with 8 neurologists was convened. The 
perspective was that of the Social Insurance Fund, and unit costs were taken from 
officially published sources (Ministry of Health and Social Insurance Fund). Primary 
and secondary analyses were carried out, in which the treatment algorithm was 
based on trial data and was adapted to the Greek setting, respectively. Deterministic 
and probabilistic sensitivity analyses were conducted to test the model’ results. In 
addition, a budget impact analysis (BIA) was carried out to estimate the annual 
cost of treating uncontrolled epileptic patients in Greece. Results: Treatment with 
LCM was shown to be dominant compared to standard therapy, as it is associated 
with 38 additional QALYs and reduced cost by € 410,024 and € 754,684 in the primary 
resource utilisation and the costs associated with health care management of MS 
in Slovakia and to provide a basis for cost-effectiveness evaluations. MethOds: 
Descriptive epidemiological data of 2,552 MS patients from 27 MS-centers across 
Slovakia were collected electronically and analyzed. In 152 selected patients fol-
lowed up in 2011-2012 in 34 MS centers, all types of health care services and costs 
were analyzed. These patients were randomly included in the study. Continuous 
variables were calculated using standard descriptive statistical methods. Results: 
77% of patients had the relapsing-remitting form of MS (RRMS); 60 % of patients 
were in EDSS 1-3, mean age of patients at the time of diagnosis was 32.3 (± 9.7) years, 
and 68% of patients were females. Total direct health care costs, DMT excluded, 
ranged from € 752 to EDSS 1 to € 2,839 to EDSS 7, being the lowest for EDSS9 (at 
€ 963). Costs for DMT ranged from € 8,584 for EDSS1 to € 13,026 in EDSS4, being lower 
for EDSS6 (€ 1,668) and none for EDSS7-9.67% patients were receiving 1st line DMT, 
and 14 % receiving 2nd line treatment. DMT was mostly applied in EDSS 2 (97%). 
The most frequently used DMTs were glatiramer acetate (20%), interferon beta-
1a IM (15%), natalizumab (9%) and fingolimod (5%). The most expensive grade 1/2 
adverse events were abdominal pain (46.62 € ), pain in joints, back and arms (39.35 € ). 
cOnclusiOns: This cross-sectional study determined the average annual direct 
cost per MS patient to be € 1,640; DMT excluded. As the EDSS increases, DMT costs 
decrease (except of EDSS1-2) and the costs of medical devices rise.
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Objectives: In Spain, Parkinson Disease Associations (PDA) offers a wide range of 
care services with partial and variable financial support from the government. The 
study objective was to estimate the costs of PDA services and to calculate the poten-
tial savings that they represent to the National Health System (NHS). MethOds: 
A survey conducted by the Federation of PDA collected information on their loca-
tion, number of members, type and use by patients of the offered services. Services 
were classified according to whether or not they were financed by the NHS, based 
on the existing national portfolio for reimbursed services. Weekly use was recorded 
and costs were calculated upon official rates (updated to € , 2014). Potential savings 
for the NHS were estimated by calculating the weekly cost associated to unfinanced 
services that were provided by the PDA. Results: 42 Spanish PDA that embraced a 
total of 11,420 patients participated in the study. From the 26 services offered, speech 
therapy (n= 41), physiotherapy (n= 39), cognitive stimulation (n= 23) and occupa-
tional therapy (n= 23) were the most frequently offered and used. The weekly cost 
associated to the provided services was € 655,219.87 [mean: € 15,980.97 (SD: 22,662.98)] 
per PDA. 53.8% of services were classified as potentially refundable by the NHS. Costs 
assaignable to potentially financed services represented 78.29%, reaching savings for 
the NHS of € 512,971.60/week. The cost of physiotherapy (27.3%) and of the adapted 
transport (21.3%) were the main components. Costs attributable to services not usually 
financed by the NHS accounted for 21.71% (€ 142,248.23), mostly attributable to cognitive 
stimulation costs (63.39%). cOnclusiOns: PDA offer valuable services to patients and 
carers and afford a major proportion of the costs of the supportive and complementary 
care of the disease. Their economic efforts imply great savings to the NHS in Spain.
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Objectives: To compare clinical outcomes (reduction in relapse number) and 
costs associated with multiple sclerosis (MS) treatment with one of the interferon 
β in the Czech Republic in five-year horizon based on development of neutral-
izing antibodies (NAbs) and patient non-adherence. Intramuscular (IM) interferon 
β -1a is characterized by very high adherence rate and low rate of NAbs produc-
tion. MethOds: Markov cohort model was developed with one-year cycle length. 
In the Czech Republic, patients with MS initiate treatment with one of the interferon 
β . NAbs-positive patients (in the model, NAbs are detected during the second year of 
treatment and thereafter) are switched/escalated to a different disease modifying 
drugs; DMD (glatiramer acetate, fingolimod, natalizumab). If patients experience 
two or more relapses during one year of treatment, they are escalated to fingoli-
mod or natalizumab. Adherence data, development of NAbs, relapse rate and costs 
were sourced from the literature. Results: One hundred patients, who initiated 
treatment with IM interferon β -1a, experienced 287 relapses over 5 years. Those, 
who started treatment with subcutaneous (SC) interferon β -1a and interferon β -1b, 
experienced by 15 and 19 relapses more. In one hundred patients, total cost of 
treatment with IM interferon β -1a was 6.4 million € . This was about 139-200 thou-
sand € less compared to SC interferon β -1a and interferon β -1b. Hence incremental 
cost-effectiveness ratio was -262 thousand € /relapse avoided and -285 thousand 
€ /relapse avoided. cOnclusiOns: Intramuscular interferon β -1a represents domi-
nant intervention in MS treatment, i. e. cost-saving treatment from payer’s perspec-
tive and simultaneously more efficacy intervention in terms of reduction in number 
of relapses due to better patient adherence and lower incidence of NAbs compare 
to the other interferons β in the Czech Republic. The one-way sensitivity analyses 
showed that results are the most sensitive to DMD costs and relapse rate.
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with 44 mcg scIFNβ 1a in patients with EDSS > 3.5–5.0 was 1.21 per patient over 2 
years. The mean number of relapses avoided for the overall study population was 
0.74 per patient over 2 years. The average cost-effectiveness of 44 mcg scIFNβ 1a 
was estimated to be $107,861 per relapse avoided for the EDSS > 3.5–5.0 cohort. The 
average cost-effectiveness for the overall study population was estimated to be 
$181,208 per relapse avoided. Sensitivity analyses showed that results were robust 
to changes in key input parameters such as DMD costs, the number of relapses in 
untreated patients, the relative risk reduction in clinical relapse rates, the rate of 
adherence, and the average cost of relapse. cOnclusiOns: Based on model results, 
the average cost-effectiveness of 44 mcg scIFNβ 1a was favorable for both the overall 
study population and the EDSS > 3.5–5.0 cohort.
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Objectives: To estimate the cost-utility of sacral anterior root stimulation (SARS, 
using the Finetech-Brindley device) compared to medical treatment (anticholiner-
gics + catheterization) in complete spinal cord injured patients with a neurological 
bladder. MethOds: A probabilistic Markov model was elaborated with a 10-year 
time-horizon, one-year cycles and a 2.5% discount rate. Three irreversible states 
were defined: 1) treatment without urinary complication; 2) surgery for urinary com-
plication (sphincterotomy, urinary derivation); 3) death. Reversible states (urinary 
calculi; Finetech-Brindley device failures) were integrated in the two first irreversible 
states. A systematic review and meta-analysis were performed to estimate transi-
tion probabilities and Quality Ajusted Life Years (QALYs). In the perspective of the 
French Healthcare System, costs were estimated from a published comparative 
cost-effectiveness research (Neurosurgery 2014; 73: 600), and through simulations 
using the 2013 French prospective payment system (PMSI) classification. Results: 
In the primary analysis, the cost-utility ratio was 10,647€ /QALY gained. At a 30,000€ 
ceiling ratio the probability of SARS being cost-effective compared to medical treat-
ment was 63%. If the French Healthcare System reimbursed SARS for 200 patients/
year the two first years and 50 patients/year during 8 years (anticipated target 
population) the expected incremental net health benefit would be 222 QALYs, and 
the expected value of perfect information (EVPI) would be 4,570,000€ . The highest 
partial EVPI is reached for transition probabilities toward urinary calculi (4,420,000€ ). 
With discount rates of 1% and 6% the cost-utility ratios were 6,951 and 19,770€ /
QALY gained, and the probabilities of SARS being cost-effective were 66% and 58%, 
respectively. cOnclusiOns: Our model shows that SARS using Finetech-Brindley 
device offers the most important benefit and should be considered cost-effective 
at a 30,000€ ceiling ratio. Despite a high uncertainty, EVPI and partial EVPI may 
indicate that further research would not be profitable to inform decision making.
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Objectives: Multiple sclerosis (MS) is a disease with lifelong impact, making the 
cost-effectiveness (CE) of its treatments particularly sensitive to assumptions 
embedded in model designs. Traditional sensitivity analysis (SA) can test many 
assumptions, but it is not designed to investigate sensitivity to structural assump-
tions. The aim of this study was to compare a Markov cohort model (MM) and a 
discrete-event simulation (DES) model of MS that were based on common clinical 
data but developed independently to understand the impact of their structural dif-
ferences on model predictions. MethOds: A similar population was simulated in 
the MM and the DES model; aggregated cost and utility estimates were compared 
over varying time horizons. The average expanded disability status scale (EDSS) and 
the distribution of EDSS were also compared over time to study the dynamics of 
disease progression and treatment effects. Results: The two modeling approaches 
led to different natural history behavior over longer time horizons, even after short-
term behaviors were well-aligned, with the DES model predicting slightly fewer 
life-years (25.9 vs. 26.2 in the MM) but more quality-adjusted life-years (9.6 vs. 8.1 
in the MM). These differences reflect slower progression of EDSS in the DES model, 
particularly to higher EDSS states. When disease history (including a baseline EDSS 
term) was excluded from the DES model, the natural history simulations of the 
two models agreed more closely. cOnclusiOns: Structural SA can help quantify 
the impact of key modeling decisions. In this study, a comparison of an MM and 
a DES model showed that natural history predictions diverge over long time hori-
zons, in part due to the consideration of disease history in the DES model. A better 
understanding of the differences between the two model designs helps ensure 
interpretation of the model results while taking into consideration the assumptions 
embedded in those designs.
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Objectives: To evaluate the cost-effectiveness of glatiramer acetate (Copaxone®) 
as a disease-modifying treatment (DMT) for relapsing-remitting multiple scle-
rosis (RRMS) compared to intravenous [natalizumab (Tysabri®), alemtuzumab 
(Lemtrada®) ] or subcutaneous injectables [interferon-beta-1b (Betaferon®), inter-
feron-beta-1a 44mcg, 22mcg, 30mcg (Rebif-44®, Rebif-22®, Avonex®) ] and oral DMTs 
[fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), teriflunomide (Aubagio®)].  
MethOds: A Markov model followed patients over 50 years through 21 health 
and secondary analysis, respectively. Extensive sensitivity analyses indicated that 
results were robust. The most influential parameters were the utility estimates, 
probability of hospitalization per seizure and unit cost of hospitalization. The BIA 
showed that the annual cost of treating uncontrolled epileptic patients with LCM 
in Greece ranges between € 274.9 and € 271.5 million, in the primary and secondary 
analyses, respectively, compared to the respective costs with standard AED (€ 277.3 
and € 279.9 million). cOnclusiOns: LCM appears to be both less costly and more 
effective compared with standard AED treatment in Greece and results in cost sav-
ings ranging between € 2.4 and € 8.3 million. Study funded by UCB Pharma.
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Objectives: To estimate the cost-effectiveness of Interferon beta-1a subcutane-
ous (SC) when compared with Interferon beta-1a intramuscular (IM) in Portugal, 
based on the findings published by the Cochrane review of first-line treatments for 
relapse-remitting multiple sclerosis. MethOds: An Excel-based model estimated 
the number of relapses and costs incurred by a cohort of 3,000 patients treated 
with two types of interferon beta-1a. The model evaluated the consequences of 
each treatment based on the findings of a Cochrane meta-analysis (Filippini 2013). 
The analysis was performed from a Portuguese NHS perspective, including only 
direct costs. Costs of relapse were obtained from a local publication (Mateus C, 
2000) whereas costs of both drugs were obtained from local official databases (Cat@
logo). Although efficacy was kept constant as Cochrane did not report outcomes 
based on EDSS, costs of relapse were available for patients with different EDSS 
values, thus allowing estimation of cost-effectiveness for different types of popu-
lation. Results: According to the model, over a 2 year period and in a population 
with EDSS ≤ 3, treatment with IM interferon beta-1a will result in a total of 2,228 
relapses, and a total cost of 69,572,717€ , whereas treatment with SC interferon beta-
1a will result in 1,709 relapses and a total cost of 70,480,835€ . For a population with 
EDSS between 3.5 and 4.5 cost values for IM and SC are 72,141,975€ and 72,451,135€ , 
respectively. Cost-effectiveness ratios were 1,748€ per relapse avoided when EDSS ≤ 
3 and 595€ per relapse avoided when EDSS was between 3.5 and 4.5. cOnclusiOns: 
Considering that the cost of a relapse varies between 3,896€ (EDSS ≤ 3) and 5,139€ 
(EDSS between 3.5 and 4.5) the incremental cost-effectiveness ratios found for 
interferon beta-1a SC seem to indicate that that SC interferon beta-1a is a cost-
effective alternative to the use of IM interferon beta-1a.
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Objectives: To investigate the cost-effectiveness of treating vs. not treating 
obstructive sleep apnea (OSA) in Italy and France MethOds: A 5-year, 10-state 
Markov model with disease states including; disease and event-free with OSA, dia-
betes, hypertension, myocardial infarction [MI], post-MI, stroke, post-stroke, atrial 
fibrillation [AF], heart failure [HF], and death; was developed to compare costs, out-
comes, and event-free life-years (LYS) of treating vs not treating OSA from the Italian 
National Health Service (INHS) and French National Health System (FNSH) view-
point. Health care resources included those related to diagnosis, treatment (CPAP 
only) and follow-up of OSA; management of hypertension, diabetes, HT, AF, post MI, 
and post-stroke (per year); MI, and stroke (per episode). Health care resources were 
valued at Euro (€ ) 2012 using published sources. Results: After 5 years the number 
of incremental event-free LYS per patient treated for OSA reaches 0.31 (Italy: 4.15 
vs 3.84; France: 4.07 vs 3.76). Treating OSA incurs an incremental cost of € 1011.01 
and € 2998.45per patient for Italy and France, respectively. The ICER of treating OSA 
is € 3212.39 for Italy and € 9777.09 for France, respectively. cOnclusiOns: Treating 
OSA can be considered highly cost-effective for both the INHS and the FNSH when 
compared to the acceptability range for incremental cost effectiveness proposed 
for Italy (€ 25,000-€ 40,000) and for Europe (€ 50,000).
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Objectives: To evaluate the cost-effectiveness of 44 mcg subcutaneous interferon 
beta-1a (scIFNβ 1a) in patients with multiple sclerosis (MS) with Kurtzke Expanded 
Disability Status Scale (EDSS) score > 3.5–5.0. MethOds: The analysis was per-
formed from a US payer perspective. The time horizon of the analysis was 2 years. 
The decision analytic model was populated with real-world inputs and related 
assumptions, as well as pivotal placebo-controlled clinical trial data for 44 mcg 
scIFNβ 1a 3 times a week (PRISMS Study). Clinical inputs were obtained for the overall 
study population as well as a subpopulation of patients with Kurtzke EDSS score 
> 3.5–5.0. Disease-modifying drug (DMD) cost was based on 2014 wholesale average 
cost with consideration of patient copayment in the base case. Sensitivity analyses 
were conducted on key input variables to assess their impact on cost per relapse 
avoided. Results: Model results showed that the mean number of relapses avoided 
